Theralase Technologies Inc.

Equities

TLT

CA88337V1004

Advanced Medical Equipment & Technology

Market Closed - Toronto S.E. Other stock markets 15:50:24 2024-06-28 EDT			5-day change	1st Jan Change
0.21 ^CAD	+10.53%		+13.51%	+20.00%

06-20	Theralase Technologies Inc. Announces Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy	CI
06-12	Theralase Technologies Inc. Announces Rutherrin Increases Efficacy of Chemotherapy	CI

Theralase Technologies Inc. Reports Earnings Results for the Half Year Ended June 30, 2023

August 29, 2023 at 04:30 pm

Theralase Technologies Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CAD 0.426087 million compared to CAD 0.552442 million a year ago. Net loss was CAD 2.56 million compared to CAD 2.95 million a year ago.

Latest news about Theralase Technologies Inc.

Theralase Technologies Inc. Announces Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy	06-20	CI
Theralase Technologies Inc. Announces Rutherrin Increases Efficacy of Chemotherapy	06-12	CI
Theralase Technologies Inc. Announces Ruvidar Enhances Efficacy of Cancer Drug	06-10	CI
Theralase Technologies Inc. Successfully Destroys Lung Cancer	06-06	CI
Theralase® Technology Effective in Virus Inactivation	06-04	CI
Theralase Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-30	CI
Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding	04-23	CI
Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent	04-05	CI
Theralase Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Theralase Technologies Donates Cool Laser Therapy Technology to Aid in R&D of Treatment for Parkinson's Disease	02-12	MT
Theralase Technologies Closes C$1.2-Million Private Placement of Share Units	02-05	MT
Theralase Technologies Inc. announced that it has received CAD 1.200001 million in funding	02-04	CI
Theralase Technologies Provides Update on Phase II Bladder Cancer Clinical Study	01-15	MT
Theralase Technologies Inc. Provides Update on Phase II Bladder Cancer Clinical Study	01-15	CI
Theralase Technologies Raises C$1.17 Million in a Private Placement of Share Units	11-29	MT
Theralase Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
Theralase Technologies Inc. announced that it has received CAD 1.17 million in funding	11-28	CI
Theralase Technologies Raising up to C$1.5 Million in a Private Placement of Share Units	11-17	MT
Theralase Technologies Inc. announced that it expects to receive CAD 1.5 million in funding	11-16	CI
Theralase® Technologies Inc. Announces That It Has Been Granted Clinical Trial Application Amendment by Health Canada Through Receipt of A No Objection Letter for the Optimization of the Phase Ii Non-Muscle Invasive Bladder Cancer Clinical Study	23-10-23	CI
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study	23-10-16	CI
Theralase Technologies Inc. Files US Patent for Enhanced Immunotherapy	23-10-05	CI
Theralase®? Technologies Inc. Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer	23-09-27	CI
Theralase Technologies Inc. announced that it has received CAD 0.46 million in funding	23-09-06	CI
Theralase Technologies First-Half Loss Narrows Even as Revenue Declined by 23%	23-08-29	MT

Chart Theralase Technologies Inc.

Duration

Period

More charts

Company Profile

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Companyâs medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.21 CAD

Average target price

0.8 CAD

Spread / Average Target

+280.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Laser Equipment

	1st Jan change	Capi.
THERALASE TECHNOLOGIES INC.	+20.00%	36.72M
EL.EN. S.P.A.	-4.41%	810M
SISRAM MEDICAL LTD	-31.56%	216M
LAMEDITECH CO., LTD.	-.--%	121M
LASEROPTEK CO., LTD.	-26.78%	84.74M
MODULIGHT OYJ	+0.51%	55.64M

Laser Equipment